<Review>MET-88 : Sarcoplastic Reticulum Ca^<2+>-Uptake Stiumlator for Treating Chronic Heart Failure
スポンサーリンク
概要
- 論文の詳細を見る
MET-88,an inhibitor of γ-butyrobetaine hydroxylase, can be characterized as a unique cardioprotective agent for the treatment of congestive heart failure (CHF) with an ability to regulate the activity of SR Ca^<2+>-ATPase. MET-88 protected the hypoxic and ischemic myocardium due to the modulation of myocardial metabolism and improved cardiac remodeling and hypertrophy as effectively as captopril. MET-88 also increased the failed Ca^<2+>-ATPase activity in the Sarcoplastic reticulum (SR), which increase might have resulted from ATP synthesis through glycolysis. These effects of MET-88 may be expected to improve mortality, prognosis, and exercise intolerance in CHF patients. In summary, MET-88 may be a useful drug for the treatment of CHF.
- 岐阜薬科大学の論文
- 2000-06-30
著者
関連論文
- P-102 COLLABORATIVE WORK TO EVALUATE TOXICITY ON MALE REPRODUCTIVE ORGANS BY REPEATED DOSE STUDIES IN RATS. : 28)DETECTION OF 1, 3-DINITROBENZENE-INDUCED HISTOPATHOLOGICAL CHANGES IN TESTES AND EPIDIDYMIDES OF RATS WITH 2-WEEKS DAILY REPEATED DOSING.(Proc
- COLLABORATIVE WORK TO EVALUATE TOXICITY ON MALE REPRODUCTIVE ORGANS BY REPEATED DOSE STUDIES IN RATS : 26)DETECTION OF 1, 3-DINITROBENZENE-INDUCED HISTOPATHOLOGICAL CHANGES IN TESTES AND EPIDIDYMIDES OF RATS WITH 2-WEEK DAILY REPEATED DOSING
- MET-88 : Sarcoplastic Reticulum Ca^-Uptake Stiumlator for Treating Chronic Heart Failure